Key result
Compound 14 reduced mortality at an oral dose of /kg in mice infected with poliovirus-2 and prevented paralysis in mice infected with ECHO-9 virus.
Compound 14 demonstrates significant in vivo efficacy against picornaviruses in mouse models, making it a candidate for clinical evaluation.
This is the authors' abstract. We don't add key points for this paper.
A series of [[(4,5-dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles has been synthesized and evaluated as antipicornavirus agents. The effect of alkyl groups in the 4- and 5-position of the oxazoline ring, as well as the alkyl chain length, on antiviral activity was examined. Compound 14 was evaluated in vivo and was found to significantly reduce mortality at an oral dose of 4 mg/kg in mice infected intracerebrally with poliovirus-2. Compound 14 was also effective in preventing paralysis when administered intraperitoneally to mice infected subcutaneously with a lethal dose of ECHO-9 virus. On the basis of the results of these studies, compound 14 is a strong candidate for clinical evaluation as a systemic agent for the treatment of picornavirus infections.
Answers are grounded in this paper and cite their sources.
Supports advancement to human trials for picornavirus infections; leaves open efficacy and safety from animal data alone.
No takes yet. Share an insight, caveat, or question.
DIANA et al. (1985) studied Picornavirus infections. Compound 14 was evaluated on Mortality and paralysis. Compound 14 reduced mortality at an oral dose of /kg in mice infected with poliovirus-2 and prevented paralysis in mice infected with ECHO-9 virus.
Synapse has enriched 10 related papers. Consider them for comparative context: